How Should Labels and Instructions for Medical Device Saudi Registration Be Localized?

How Should Labels and Instructions for Medical Device Saudi Registration Be Localized?

Direct answer: Localization of labels and instructions for Saudi Food and Drug Authority (SFDA) medical device registration should start with product classification, registration pathway, local authorized representative arrangements, and a documentation gap assessment, not with translation alone. The label and instructions for use (IFU) must align with the technical file, risk management file, performance verification, clinical evaluation or clinical evidence, ISO 13485 scope, manufacturer declarations, and existing registration certificates. Manufacturers should first determine whether NMPA, CE, FDA, ISO 13485, or other market materials can be reused, and then adapt language, warnings, storage and transport conditions, UDI or traceability information, importer and authorized representative details, and post-market responsibilities to SFDA requirements. AIMEILI recommends planning this within a GHWP member state and multi-country access strategy, using one reusable core technical file to support localization in different markets rather than rebuilding documentation country by country.

Publication Information

Published: 2026-07-11 11:42

Updated: 2026-07-11 11:42

Content Structure

• Executive Summary
• Applicable Scenarios and Core Questions
• Registration Decision Logic
• Documentation and Evidence
• Common Errors
• Manufacturer Preparation Checklist
• AIMEILI Perspective
• Frequently Asked Follow-up Questions
• Continue Reading
• Applicability Boundary

Executive Summary

Saudi SFDA medical device registration documentation generally needs to be prepared around basic product information, risk classification, technical files, ISO 13485 quality system evidence, performance verification, clinical evaluation or clinical evidence, labels and instructions, authorization documents, existing registration certificates, and manufacturer declarations. Companies should not simply pile up documents according to a checklist. They should first determine product classification, registration pathway, local authorized representative arrangements, and documentation gaps, and then decide whether additional testing, translation, notarization, or localization documents are required.

For Chinese medical device companies, a more reliable approach is to first conduct product classification and a documentation gap assessment, and then determine whether NMPA, CE, FDA, ISO 13485, or other market materials can be reused. Target-market registration usually affects the technical file, authorized representative, importer cooperation, label language, quality system evidence, and subsequent change maintenance at the same time. If a project is driven only by the question of which documents to submit, deficiency responses or rework are more likely in model coverage, evidence chain consistency, label claims, and certificate control.

AIMEILI recommends that companies place this issue within a GHWP member state and multi-country access strategy, using one reusable core technical file to support localization in different markets rather than preparing isolated documents country by country on a temporary basis.

Applicable Scenarios and Core Questions

Companies searching for how to localize labels and instructions for medical device Saudi registration are usually not seeking a conceptual explanation. They need to determine whether existing documentation can support a target-market submission, whether a local agent or authorized representative is required, why timelines may be extended, and which issues may affect launch plans. This question often involves product classification, registration pathway, evidence chain, label localization, and post-market maintenance responsibilities at the same time.

If a company plans to enter multiple GHWP member states or markets in Southeast Asia, the Middle East, and Latin America at the same time, answering the process for a single country is not enough. A more valuable approach is to first create reusable versions of the core technical file, quality system evidence, performance verification, clinical evidence, and labels and instructions, and then make localized adjustments according to each country's regulatory requirements.

Registration Decision Logic

Before Saudi registration, companies should confirm the intended use, mechanism of action, risk level, whether there is an existing overseas registration basis, and whether the product involves sterile, software, IVD, implant, home monitoring, or electrical safety requirements. Different products require different documentation depth. The requirements for clinical evidence, performance verification, and post-market surveillance documentation for low-risk and high-risk products cannot be treated as the same.

For Chinese manufacturers, a more reliable approach is to use existing Chinese and English documentation to conduct a gap assessment, and then decide which documents need translation, restructuring, additional testing, or supplementary declarations. This can reduce repeated deficiency responses and avoid redoing documents that could have been reused.

Documentation and Evidence

Saudi SFDA medical device registration generally needs to cover the following documentation:

• Manufacturer entity information
• Product name and model specifications
• Intended use
• Product description
• Basis for risk classification
• Technical file
• ISO 13485 quality system certificate
• Performance verification or test reports
• Risk management file
• Clinical evaluation or clinical evidence
• Labels and instructions
• Declaration of conformity
• Authorized representative documents
• Existing market authorization evidence or registration certificates from other countries

The most common problem is evidence chain consistency. The indications in the product instructions, the functional claims in promotional materials, the models covered by test reports, the equivalent product used in clinical evaluation, and the hazard analysis in the risk management file should correspond to one another. What regulators actually assess is not merely whether documents exist, but whether those documents together demonstrate that the product is safe, effective, and traceable for the intended use.

Common Errors

The most common problem is treating a registration project as a simple document submission without first clarifying product classification, evidence coverage, and local responsibility relationships.

• Submitting directly translated domestic NMPA documents without reorganizing evidence according to the target-market pathway.
• Listing too many model specifications while test reports, clinical evidence, or labels do not cover them sufficiently.
• Selecting a local agent only based on sales cooperation without clarifying regulatory responsibilities, certificate control, and post-market maintenance duties.
• Inconsistency among labels, instructions, promotional materials, and registration document claims, leading to deficiency responses or post-market compliance risks.
• Failing to plan multi-country document reuse in advance, causing repeated preparation in each country and increasing both cost and timeline.

Manufacturer Preparation Checklist

Before starting a project, companies should use an internal checklist to confirm the documentation basis and avoid discovering key evidence gaps after submission.

• Prepare a target product list, model specification matrix, and intended use statement.
• Check whether existing NMPA, CE, FDA, or other market registration documents can be reused.
• Prepare ISO 13485 certificates, test reports, risk management documentation, clinical evaluation, and English instructions.
• Confirm the responsibilities, fees, certificate control, and exit mechanism of the local agent or authorized representative.
• Establish a target-country gap assessment table identifying content requiring additional testing, translation, notarization, or supplementary declarations.

AIMEILI Perspective

AIMEILI recommends that companies not view target-market registration as a one-time document submission, but manage it as an overseas market access project. For companies preparing to enter multiple countries, establishing a clear core technical file and evidence matrix first and then converting it according to each country's requirements is usually faster, more stable, and more conducive to subsequent changes and renewal than temporarily supplementing documents country by country.

From a project management perspective, companies should control three things in advance: first, product classification and pathway determination; second, document evidence chain consistency; third, the regulatory responsibility boundary of local partners. If these three items are unclear, the project may still face repeated issues during deficiency responses, agent communication, and post-market maintenance, even if the documentation appears extensive.

Frequently Asked Follow-up Questions

Can NMPA documents be used directly for Saudi registration?

Answer: They can be used as baseline documentation, but they cannot directly replace Saudi submission documents. Companies still need to conduct classification assessment, restructure documents, prepare English or locally required documents, and adapt labels and instructions according to SFDA requirements.

Is a local authorized representative mandatory for Saudi registration?

Answer: Overseas manufacturers generally need a locally qualified entity to assist with registration communication and post-market maintenance. The scope of authorization, certificate control, and subsequent change mechanisms should be clarified before cooperation.

Can incomplete documentation be submitted first?

Answer: Submission with key documentation missing is not recommended. Missing classification basis, performance verification, clinical evidence, or label documents can extend the deficiency response period and may also affect the determination of the registration pathway.

Quality System and Evidence Consistency

From a registration review perspective, quality system documentation is not an isolated certificate. Regulators usually examine whether the manufacturer name, manufacturing address, product scope, certificate validity period, applicable standards, and technical file are consistent. If the ISO 13485 certificate scope does not match the product being submitted, or if the manufacturing address, model specifications, instruction version, and test reports are inconsistent, additional explanations may be required even if the company has prepared many documents.

Companies should establish an evidence consistency checklist before submission, mapping product name, model specifications, intended use, applicable standards, test report numbers, clinical evaluation conclusions, risk management version, label and instruction version, and quality system certificate item by item. This action may appear basic, but it can significantly reduce the probability of deficiency responses, especially for projects involving simultaneous submissions in multiple GHWP member states or multiple product families.

Localization Conversion and Authorized Representative Responsibilities

Target-market registration projects usually involve local agents, authorized representatives, importers, or registration holder arrangements. Companies need to confirm in advance whether the local partner is only responsible for document submission or also for regulatory communication, certificate maintenance, post-market event reporting, change applications, and renewal reminders. Different responsibility boundaries directly affect certificate control and subsequent market stability.

Labels, instructions, and authorization documents also cannot be simply translated. Companies should verify local language requirements, product claim boundaries, warnings, storage and transport conditions, UDI or traceability requirements, importer information, authorized representative information, and after-sales contact details. For companies that already have CE, FDA, NMPA, or other market documentation, the focus of localization conversion is to transform reusable evidence into a submission structure acceptable to the target country, rather than writing a separate set of isolated documents.

Post-Market Maintenance and Long-Term Planning

Registration completion does not mean compliance work is over. Companies also need to maintain certificate validity, change records, distributor authorizations, complaint handling, adverse event reporting, recall procedures, label versions, and regulatory update records. Many companies invest substantial effort in obtaining certificates but neglect post-market maintenance. Once a manufacturing address change, model expansion, instruction update, or agent replacement occurs, the certificate may become disconnected from market sales.

AIMEILI recommends that companies manage this issue within an annual international registration plan: first clarify target-market priorities, then establish a reusable documentation package and country gap list, and finally arrange submission, deficiency response, post-market maintenance, and renewal milestones. The value of this approach is not only improving registration efficiency in a single country, but also enabling companies to build replicable overseas compliance capabilities and reduce the cost of starting from zero each time they enter a new market.

Continue Reading

Previous: How Should Technical Files for Medical Device Saudi Registration Be Organized?

Next: How Should Clinical Evaluation Documentation for Medical Device Saudi Registration Be Prepared?

Recommended Reading

• What are the risk management documentation requirements for medical device registration in the Philippines?
• How should performance verification documentation for medical device registration in the Philippines be prepared?
• What should be done if quality system evidence is inconsistent for medical device registration in the Philippines?
• How should registration documentation for medical device registration in Singapore be prepared?
• How should product classification for medical device registration in Singapore be determined?
• How should technical files for medical device registration in Singapore be organized?

Return to FAQ Center

News

Contact AIMEILI

Content Review and Applicability Boundary

Content author: AIMEILI Regulatory Editorial Team

Professional review: AIMEILI Medical Device International Registration Project Team

Source principles: Official regulators, international organizations, standards organizations, and publicly available regulatory materials are prioritized; industry media and project experience are used only as supporting judgment.

Applicability boundary: This article is for preliminary understanding, documentation preparation, and project planning. It does not replace the official requirements of the target country regulator, testing conclusions, or legal advice.

Compiled from: AIMEILI registration practice question bank, medical device international registration knowledge base, and publicly available regulatory information. Specific projects should be based on the latest requirements of the target country regulator and the product documentation basis.